Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Neuroacanthocytosis Syndromes Workup

  • Author: Kenneth B V Gross, MD; Chief Editor: Selim R Benbadis, MD  more...
 
Updated: Mar 19, 2014
 

Laboratory Studies

Several laboratory tests are essential for the diagnosis of neuroacanthocytosis (NA) and its variant syndromes.

Any adult with chorea and orofacial tics should have a complete blood count (CBC) and RBC morphology analysis for acanthocytes. Acanthocytes are usually present in fewer than 50% of the total RBC specimens in NA and its variants. At some point during the course of the disease, most patients with NA exhibit acanthocytosis on peripheral blood smear. This study may need to be repeated periodically to demonstrate this finding.

CPK levels should be checked in any adult with a midlife onset of a movement disorder. CPK levels in the range of 300-1000 IU/L are found in NA and its variants in the absence of a clear clinical myopathy and beyond what typically is noted in other choreiform disorders. However, Dotti has noted higher CK levels in patients with McLeod syndrome (reaching 3000) typically in association with the attendant myopathy.[26] Fractionation of CPK is reasonable if it is high, although usually the CPK is almost exclusively of the MM type.

Kell blood typing is required to rule out the NA-linked McLeod syndrome. The McLeod phenotype is characterized by weakened expression of antigens in the Kell blood group system and absence of Km and Kx antigens in addition to acanthocytosis. Suspicion is highest for the presence of the Kell null McLeod phenotype when only males in a given family have NA and cardiomyopathy is associated with the neurologic syndrome. Such patients may have a less severe movement disorder and more acanthocytosis-related hemolysis than what is noted in the more common form of NA, presumably due to a chromosome 9 defect.

Patients with a high CPK level and acanthocytes should also have Kell phenotyping done.

A lipid profile that includes lipoprotein analysis is reasonable in all patients with NA, particularly in young patients who have Bassen-Kornzweig features (eg, retinitis pigmentosa) along with more characteristic adult-onset NA features (eg, chorea). Normal lipid profile is of course most consistent with NA, but hypolipoproteinemia is common in NA variant syndromes.

Thyroid, prolactin, and growth hormone levels in adults with NA may be abnormal.

Genetic studies to rule out a gene abnormality in chromosome 9, the presumptive site for the most common (autosomal recessive) type of NA, may be useful in defining subclinical or variant cases. Low or absent levels of chorein protein via a blood assay are noted in patients with recessive NA. Rarely, NA can occur as a spontaneous mutation. Even in this group ruling out a chromosome 9 genetic defect or a Kell X chromosome anomaly may be helpful.

Next

Imaging Studies

Brain MRI or CT scan is helpful in assessing caudate atrophy, which is characteristic of NA and its variants, including McLeod syndrome. Generalized mild cortical atrophy is also common, in addition to increased signal intensity lesions in the cerebral hemispheric white matter on MRI[27] . Hippocampal atrophy may be found in patients with temporal lobe seizures.

Neuroimaging typically shows basal ganglia atrophy, which correlates with disease duration.

Cerebellar atrophy on MRI has also been reported in a pair of siblings with NA.

MRI and CT scan are of greater value in looking for other causes of chorea in an adult, such as that due to cerebrovascular disease or a mass lesion.

MRI can demonstrate iron in the basal ganglia, typically noted in HS but not in NA.

In reports of the patients with autosomal forms of NA, brain single-photon emission computed tomography (SPECT) or positron emission tomography (PET) can confirm striatal hypometabolism, which on FDG-PET correlates with disease duration. In addition, striatal hypometabolism on FDG-PET has been reported in 2 unrelated patients with McLeod syndrome, even in the absence of chorea in one of those men.

Previous
Next

Other Tests

Needle EMG and nerve conduction studies are indicated. Denervation atrophy with a distal motor axonal neuropathy is the typical finding in NA. However, a sensory axonal neuropathy also has been described. Patients with McLeod syndrome can show myopathic changes in addition to evidence of neurogenic atrophy and axonal neuropathy.

Echocardiography is recommended in patients with clinical evidence of NA and cardiac dysfunction. In these patients, cardiomyopathy should be ruled out. Mitral valve prolapse, concentric left ventricular hypertrophy, increased septal thickness, and generalized hypokinesia all have been described.

Patients with McLeod syndrome (who often have more dangerous cardiac problems than skeletal muscle difficulties) frequently have echocardiographic abnormalities including left ventricular hypertrophy. Cardiac biopsy in a recently described McLeod cardiomyopathy case revealed focal myocyte hypertrophy, slight variation of myofiber size, and patchy interstitial fibrosis.

EEG can be valuable because some patients will have seizures. A recent report documented a temporal lobe focus in a patient with NA and focal seizures.

Abnormalities in saccades and pursuits on neuro-ophthalmologic testing have been described. In addition, a high number of square wave jerks on eye movement evaluation has been reported, implicating brain stem dysfunction in patients with NA with VPS13A mutations.[28]

Previous
Next

Procedures

Lumbar puncture can be of value to rule out an infectious etiology such as syphilis or AIDS or an autoimmune disease. Cerebrospinal fluid (CSF) in NA is typically normal.

If a patient has acanthocytosis and a high CPK level, performing a muscle biopsy is reasonable to rule out a component of the myopathy that can occur in patients with NA, either as a late manifestation of neurogenic disturbances in the muscle or as linked to the more characteristic myopathic disorder in McLeod syndrome. The main indication for muscle biopsy is to exclude the presence of a myositis that requires therapy. In some patients with hemolysis and a high CPK level, a muscle biopsy may be necessary to rule out polymyositis.

Sural nerve biopsy to rule out inflammatory changes may be valuable in any patient with NA and neurophysiological evidence of a neuropathy, particularly since anti-ganglioside antibody titers have been described in one NA variant with neuropathy.

Previous
Next

Histologic Findings

Muscle biopsy changes in NA indicate neurogenic atrophy. Although a high percentage of central nucleation and longitudinal splitting indicated some degree of myopathy in a McLeod variant case, these are nonspecific myopathic findings. Even McLeod cases have high rates of neurogenic atrophy in skeletal muscle as opposed to a less common biopsy-proven primary skeletal myopathy.

Sural nerve biopsy shows varying degrees of myelinated fiber dropout, with selective reduction in the large-diameter myelinated fiber population. This is noted in most patients with NA, both classic and variant types. These findings are nonspecific.

Neuropathy is a major distinguishing factor differentiating (where neuropathy is present) HD from NA. With autopsy, the disorders are further distinguished. Although both disorders show prominent caudate atrophy, HD (where neuropathy is absent) may be associated with prominent cortical atrophy and low caudate levels of glutamic acid decarboxylase and choline acetyltransferase. These biochemical determinations are not part of routine neuropathologic autopsy protocols.

Previous
 
 
Contributor Information and Disclosures
Author

Kenneth B V Gross, MD Founder, Owner, Fusion Clinical Multimedia, Inc, Division of Neurology, Fusion Clinical Multimedia Educational Center

Kenneth B V Gross, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Coauthor(s)

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Nestor Galvez-Jimenez, MD, MSc, MHA The Pauline M Braathen Endowed Chair in Neurology, Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cyberonics; Eisai; Lundbeck; Sunovion; UCB; Upsher-Smith<br/>Serve(d) as a speaker or a member of a speakers bureau for: Cyberonics; Eisai; Glaxo Smith Kline; Lundbeck; Sunovion; UCB<br/>Received research grant from: Cyberonics; Lundbeck; Sepracor; Sunovion; UCB; Upsher-Smith.

Additional Contributors

Roberta J Seidman, MD Associate Professor of Clinical Pathology, Stony Brook University; Director of Neuropathology, Department of Pathology, Stony Brook University Medical Center

Roberta J Seidman, MD is a member of the following medical societies: American Academy of Neurology, Suffolk County Society of Pathologists, New York Association of Neuropathologists (The Neuroplex), American Association of Neuropathologists

Disclosure: Nothing to disclose.

References
  1. Levine IM, Estes JW, Looney JM. Hereditary neurological disease with acanthocytosis. A new syndrome. Arch Neurol. 1968 Oct. 19(4):403-9. [Medline].

  2. Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol. 1968 Feb. 18(2):134-40. [Medline].

  3. Walker RH. Autosomal-dominant chorea-acanthocytosis: Report of a family and neuropathology In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

  4. Walker RH, Schulz VP, Tikhonova IR, Mahajan MC, Mane S, Arroyo Muniz M. Genetic diagnosis of neuroacanthocytosis disorders using exome sequencing. Mov Disord. 2011 Oct 28. [Medline].

  5. Redman CM, Reid ME. The McLeod syndrome: an example of the value of integrating clinical and molecular studies. Transfusion. 2002 Mar. 42(3):284-6. [Medline].

  6. van den Buuse M, Webber KM. Endothelin and dopamine release. Prog Neurobiol. 2000 Mar. 60(4):385-405. [Medline].

  7. Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol. 2001 Mar. 49(3):384-92. [Medline].

  8. Wiethoff S, Xiromerisiou G, Bettencourt C, Kioumi A, Tsiptsios I, Tychalas A. Novel single base-pair deletion in exon 1 of XK gene leading to McLeod syndrome with chorea, muscle wasting, peripheral neuropathy, acanthocytosis and haemolysis. J Neurol Sci. 2014 Feb 1. [Medline].

  9. Bosman GM. Erythrocyte membrane abnormalities in neuroacanthocytosis: Evidence for a neuron-erythrocyte axis?. Danek A, ed. Neuroacanthocytosis Syndromes. Springer; 2005.

  10. De Franceschi L, Corrocher R. Erythrocyte membrane anion exchange abnormalities in chorea-acanthocytosis: The band 3 network. Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

  11. Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol. 2004 Aug. 56(2):299-302. [Medline].

  12. Bayreuther C, Borg M, Ferrero-Vacher C, Chaussenot A, Lebrun C. [Chorea-acanthocytosis without acanthocytes]. Rev Neurol (Paris). 2010 Jan. 166(1):100-3. [Medline].

  13. Walker RH, Danek A, Uttner I, Offner R, Reid M, Lee S. McLeod phenotype without the McLeod syndrome. Transfusion. 2007 Feb. 47(2):299-305. [Medline].

  14. De Franceschi L, Tomelleri C, Matte A, Brunati AM, Bovee-Geurts PH, Bertoldi M. Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. Blood. 2011 Nov 17. 118(20):5652-63. [Medline].

  15. De Franceschi L, Scardoni G, Tomelleri C, Danek A, Walker RH, Jung HH. Computational identification of phospho-tyrosine sub-networks related to acanthocyte generation in neuroacanthocytosis. PLoS One. 2012. 7(2):e31015. [Medline].

  16. Kanjanasut N, Jagota P, Bhidayasiri R. The first case report of neuroacanthocytosis in Thailand: utilization of a peripheral blood smear technique for detecting acanthocytes. Clin Neurol Neurosurg. 2010 Jul. 112(6):541-3. [Medline].

  17. Man BL, Yuen YP, Yip SF, Ng SH. The first case report of McLeod syndrome in a Chinese patient. BMJ Case Rep. 2013. 2013:[Medline].

  18. Chakravarty A, Bhattacharya P, Banerjee D, Mukherjee S. Mcleod syndrome: Report of an Indian family with phenotypic heterogeneity. Ann Indian Acad Neurol. 2011 Jan. 14(1):53-5. [Medline]. [Full Text].

  19. Troiano AR, Trevisol-Bittencourt PC. [Neuroacanthocytosis. A case report]. Arq Neuropsiquiatr. 1999 Jun. 57(2B):489-94. [Medline].

  20. Bird TD, Cederbaum S, Valey RW, Stahl WL. Familial degeneration of the basal ganglia with acanthocytosis: a clinical, neuropathological, and neurochemical study. Ann Neurol. 1978 Mar. 3(3):253-8. [Medline].

  21. Gross KB, Skrivanek JA, Carlson KC, Kaufman DM. Familial amyotrophic chorea with acanthocytosis. New clinical and laboratory investigations. Arch Neurol. 1985 Aug. 42(8):753-6. [Medline].

  22. Neutel D, Miltenberger-Miltenyi G, Silva I, de Carvalho M. Chorea-acanthocytosis presenting as motor neuron disease. Muscle Nerve. 2012 Feb. 45(2):293-5. [Medline].

  23. Orr HT. FTD and ALS: genetic ties that bind. Neuron. 2011 Oct 20. 72(2):189-90. [Medline].

  24. Jung HH, Haker H. Schizophrenia as a manifestation of X-linked Mcleod-Neuroacanthocytosis syndrome. J Clin Psychiatry. 2004 May. 65(5):722-3. [Medline].

  25. Bruneau MA, Lespérance P, Chouinard S. Schizophrenia-like presentation of neuroacanthocytosis. J Neuropsychiatry Clin Neurosci. 2003. 15(3):378-80. [Medline].

  26. Dotti MT, Battisti C, Malandrini A, et al. McLeod syndrome and neuroacanthocytosis with a novel mutation in the XK gene. Mov Disord. 2000 Nov. 15(6):1282-4. [Medline].

  27. Nicholl DJ, Sutton I, Dotti MT, Supple SG, Danek A, Lawden M. White matter abnormalities on MRI in neuroacanthocytosis. J Neurol Neurosurg Psychiatry. 2004 Aug. 75(8):1200-1. [Medline].

  28. Gradstein L, Danek A, Grafman J, Fitzgibbon EJ. Eye movements in chorea-acanthocytosis. Invest Ophthalmol Vis Sci. 2005 Jun. 46(6):1979-87. [Medline].

  29. Volkmann J. Is surgical treatment an option for chorea-acanthocytosis? In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

  30. Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord. 2005. 20:1681-1682.

  31. Beal MF, Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proc Natl Acad Sci U S A. 2001 Jan 2. 98(1):3-4. [Medline].

  32. Robinson D, Smith M, Reddy R. Neuroacanthocytosis. Am J Psychiatry. 2004 Sep. 161(9):1716. [Medline].

  33. Habermeyer B, Fuhr P. Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram. Pharmacopsychiatry. 2007 Mar. 40(2):87. [Medline].

  34. Vázquez MJ, Martínez MC. Electroconvulsive Therapy in Neuroacanthocytosis or McLeod Syndrome. J ECT. 2008 Nov 7. [Medline].

  35. Akamatsu K, Sakaue H, Tada K, et al. A case report of abetalipoproteinemia (Bassen-Kornzweig syndrome)--the first case in Japan. Jpn J Med. 1983 Aug. 22(3):231-6. [Medline].

  36. Al-Asmi A, Jansen AC, Badhwar A, et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia. 2005 Aug. 46(8):1256-63. [Medline].

  37. Alonso ME, Teixeira F, Jimenez G, Escobar A. Chorea-acanthocytosis: report of a family and neuropathological study of two cases. Can J Neurol Sci. 1989 Nov. 16(4):426-31. [Medline].

  38. Andermann E, Jansen A, Andermann F. French-Canadian chorea-acanthocytosis. Mov Disord. 2005. 20:1678.

  39. Arimura H, Kuriyama M, Higuchi I, et al. [Paroxysmal dystonic choreoathetosis with chronic hemolytic anemia and morphologically abnormal erythrocytes]. Rinsho Shinkeigaku. 1995 Jan. 35(1):29-33. [Medline].

  40. Bansal I, Jeon HR, Hui SR, Calhoun BW, Manning DW, Kelly TJ. Transfusion support for a patient with McLeod phenotype without chronic granulomatous disease and with antibodies to Kx and Km. Vox Sang. 2008 Apr. 94(3):216-20. [Medline].

  41. Beal MF. In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer; 2005.

  42. Bharucha EP, Bharucha NE. Choreo-acanthocytosis. J Neurol Sci. 1989 Feb. 89(2-3):135-9. [Medline].

  43. Bostantjopoulou S, Katsarou Z, Kazis A, Vadikolia C. Neuroacanthocytosis presenting as parkinsonism. Mov Disord. 2000 Nov. 15(6):1271-3. [Medline].

  44. Bramanti P, Ricci RM, Candela L, et al. Sleep spindles in amyotrophic chorea-acanthocytosis disease. Acta Neurol (Napoli). 1987 Jun. 9(3):191-8. [Medline].

  45. Burbaud P, Rougier A, Ferrer X, et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord. 2002 Jan. 17(1):204-7. [Medline].

  46. Burbaud P, Vital A, Rougier A, et al. Minimal tissue damage after stimulation of the motor thalamus in a case of chorea-acanthocytosis. Neurology. 2002 Dec 24. 59(12):1982-4. [Medline].

  47. Cavalli G, de Gregorio C, Nicosia S, et al. [Cardiac involvement in familial amytrophic chorea with acantocytosis: description of two new clinical cases]. Ann Ital Med Int. 1995 Oct-Dec. 10(4):249-52. [Medline].

  48. Chorea-acanthocytosis: report of two Brazilian cases.

  49. Clapéron A, Hattab C, Armand V, Trottier S, Bertrand O, Ouimet T. The Kell and XK proteins of the Kell blood group are not co-expressed in the central nervous system. Brain Res. 2007 May 25. 1147:12-24. [Medline].

  50. Danek A, Dobson-Stone C, Velayos-Baeza A. The phenotype of chorea-acanthocytosis: a review of 106 patients with VPS13A mutations. Mov Disord. 2005. 20:1678.

  51. Danek A, Jung HH, Melone MA, et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci. 2005 Mar 15. 229-230:171-86. [Medline].

  52. Danek A, Uttner I, Vogl T, et al. Cerebral involvement in McLeod syndrome. Neurology. 1994 Jan. 44(1):117-20. [Medline].

  53. Dobson-Stone C. The spectrum of mutations and possible function of the CHAC gene In: Danek A, ed. Neuoracanthocytosis Syndromes. Springer. 2005.

  54. Faillace RT, Kingston WJ, Nanda NC, Griggs RC. Cardiomyopathy associated with the syndrome of amyotrophic chorea and acanthocytosis. Ann Intern Med. 1982 May. 96(5):616-7. [Medline].

  55. Ferrer X, Julien J, Vital C, et al. [Choreo-acanthocytosis]. Rev Neurol (Paris). 1990. 146(12):739-45. [Medline].

  56. Gil-Nagel A, Morlan L, Balseiro J, et al. [Neuro-acanthocytosis with associated myopathy. A case report]. Neurologia. 1994 Apr. 9(4):165-8. [Medline].

  57. Gross KB, Skrivanek JA, Emeson EE. Ganglioside abnormality in amyotrophic chorea with acanthocytosis. Lancet. 1982 Oct 2. 2(8301):772. [Medline].

  58. Halliday W. The nosology of Hallervorden-spatz disease. J Neurol Sci. 1995 Dec. 134 Suppl:84-91. [Medline].

  59. Hardie RJ. Acanthocytosis and neurological impairment--a review. Q J Med. 1989 Apr. 71(264):291-306. [Medline].

  60. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. 1991 Feb. 114 ( Pt 1A):13-49. [Medline].

  61. Hashimoto T, Nakadai A, Fujimori N, Yanagisawa N. [A case of "chorea with acanthocytosis and neuropathy" (chorea-acanthocytosis) with parkinsonism without areflexia]. Rinsho Shinkeigaku. 1987 Jan. 27(1):88-93. [Medline].

  62. Hewer E, Danek A, Schoser BG, Miranda M, Reichard R, Castiglioni C. McLeod myopathy revisited: more neurogenic and less benign. Brain. 2007 Dec. 130(Pt 12):3285-96. [Medline].

  63. Higgins JJ, Patterson MC, Papadopoulos NM, et al. Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology. 1992 Jan. 42(1):194-8. [Medline].

  64. Hirayama M, Hamano T, Shiratori M, et al. Chorea-acanthocytosis with polyclonal antibodies to ganglioside GM1. J Neurol Sci. 1997 Oct 3. 151(1):23-4. [Medline].

  65. Iwata M, Fuse S, Sakuta M, Toyokura Y. Neuropathological study of chorea-acanthocytosis. Jpn J Med. 1984 May. 23(2):118-22. [Medline].

  66. Katsube T, Shimono T, Ashikaga R, Hosono M, Kitagaki H, Murakami T. Demonstration of Cerebellar Atrophy in Neuroacanthocytosis of 2 Siblings. AJNR Am J Neuroradiol. 2008 Oct 22. [Medline].

  67. Kohler B. [Hallervorden-Spatz syndrome with acanthocytosis]. Monatsschr Kinderheilkd. 1989 Sep. 137(9):616-9. [Medline].

  68. Kurano Y, Nakamura M, Ichiba M, Matsuda M, Mizuno E, Kato M. Chorein deficiency leads to upregulation of gephyrin and GABA(A) receptor. Biochem Biophys Res Commun. 2006 Dec 15. 351(2):438-42. [Medline].

  69. Kuroiwa Y, Ohnishi A, Sato Y, Kanazawa I. Chorea acanthocytosis: clinical pathological and biochemical aspects. Int J Neurol. 1984. 18:64-74. [Medline].

  70. Kutcher JS, Kahn MJ, Andersson HC, Foundas AL. Neuroacanthocytosis masquerading as Huntington's disease: CT/MRI findings. J Neuroimaging. 1999 Jul. 9(3):187-9. [Medline].

  71. Larget-Piet L, Pouplard F. [Ataxia-areflexia-familial steatorrhea without abetalipoproteinemia or acanthocytosis]. J Genet Hum. 1981 Sep. 29(3):249-51. [Medline].

  72. Limos LC, Ohnishi A, Sakai T, et al. "Myopathic" changes in chorea-acanthocytosis. Clinical and histopathological studies. J Neurol Sci. 1982 Jul. 55(1):49-58. [Medline].

  73. Lin FC, Wei LJ, Shih PY. Effect of levetiracetam on truncal tic in neuroacanthocytosis. Acta Neurol Taiwan. 2006 Mar. 15(1):38-42. [Medline].

  74. Luckenbach MW, Green WR, Miller NR, et al. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. Am J Ophthalmol. 1983 Mar. 95(3):369-82. [Medline].

  75. Lupo I, Aragona F, Fierro B, et al. Choreo-acanthocytosis with myopathy. Report of a case. Acta Neurol (Napoli). 1987 Oct-Dec. 9(5-6):334-8. [Medline].

  76. Malandrini A, Fabrizi GM, Truschi F, et al. Atypical McLeod syndrome manifested as X-linked chorea-acanthocytosis, neuromyopathy and dilated cardiomyopathy: report of a family. J Neurol Sci. 1994 Jun. 124(1):89-94. [Medline].

  77. Marson AM, Bucciantini E, Gentile E, Geda C. Neuroacanthocytosis: clinical, radiological, and neurophysiological findings in an Italian family. Neurol Sci. 2003 Oct. 24(3):188-9. [Medline].

  78. Miranda M, Campero M, Tenhamm E, Villagra R. [Neuroacanthocytosis: report of 3 cases]. Rev Med Chil. 1993 Feb. 121(2):176-9. [Medline].

  79. Miranda M, Castiglioni C, Frey BM, Hergersberg M, Danek A, Jung HH. Phenotypic variability of a distinct deletion in McLeod syndrome. Mov Disord. 2007 Jul 15. 22(9):1358-61. [Medline].

  80. Mukoyama M, Kazui H, Sunohara N, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. J Neurol. 1986 Aug. 233(4):228-32. [Medline].

  81. Müller-Vahl KR, Berding G, Emrich HM, Peschel T. Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT. J Neurol. 2007 Aug. 254(8):1081-8. [Medline].

  82. Nielsen SM, Temlett JA. Neuro-acanthocytosis--a rare cause of chorea. S Afr Med J. 1997 Jul. 87(7):897-8. [Medline].

  83. Nihashi H, Yoshida M. [Cognitive function in patients with parkinsonism--in relationship with frontal lobe symptoms]. No To Shinkei. 1988 Mar. 40(3):261-6. [Medline].

  84. Oechslin E, Kaup D, Jenni R, Jung HH. Cardiac abnormalities in McLeod syndrome. Int J Cardiol. 2007 Nov 26. [Medline].

  85. Oechsner M, Buchert R, Beyer W, Danek A. Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. J Neurol Neurosurg Psychiatry. 2001 Apr. 70(4):517-20. [Medline]. [Full Text].

  86. Ogawa T, Seki H, Okita N, et al. [A case of chorea-acanthocytosis associated with low glycohemoglobin A1c]. Rinsho Shinkeigaku. 1993 Mar. 33(3):344-6. [Medline].

  87. Ohnishi A, Sato Y, Nagara H, et al. Neurogenic muscular atrophy and low density of large myelinated fibres of sural nerve in chorea-acanthocytosis. J Neurol Neurosurg Psychiatry. 1981 Jul. 44(7):645-8. [Medline].

  88. Orlacchio A, Calabresi P, Rum A, Tarzia A, Salvati AM, Kawarai T, et al. Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. BMC Neurol. 2007 Feb 13. 7:4. [Medline].

  89. Orrell RW, Amrolia PJ, Heald A, et al. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: a report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology. 1995 Mar. 45(3 Pt 1):487-92. [Medline].

  90. Parhofer KG, Richter WO, Stiess W, Schwandt P. [Acanthocytosis, short stature and disordered deep sensation in a 26-year-old patient]. Internist (Berl). 1989 Jun. 30(6):382-5. [Medline].

  91. Pisani A, Diomedi M, Rum A, Cianciulli P, Floris R, Orlacchio A, et al. Acanthocytosis as a predisposing factor for non-ketotic hyperglycaemia induced chorea-ballism. J Neurol Neurosurg Psychiatry. 2005 Dec. 76(12):1717-9. [Medline].

  92. Rubio JP, Danek A, Stone C, et al. Chorea-acanthocytosis: genetic linkage to chromosome 9q21. Am J Hum Genet. 1997 Oct. 61(4):899-908. [Medline].

  93. Ruiz-Sandoval JL, García-Navarro V, Chiquete E, Dobson-Stone C, Monaco AP, Alvarez-Palazuelos LE, et al. Choreoacanthocytosis in a Mexican family. Arch Neurol. 2007 Nov. 64(11):1661-4. [Medline].

  94. Saggese G, Baroncelli GI, Bertelloni S, et al. [Chronic granulomatous disease and McLeod phenotype. Description of a case]. Minerva Pediatr. 1990 Apr. 42(4):151-6. [Medline].

  95. Saiki S, Sakai K, Murata KY, Saiki M, Nakanishi M, Kitagawa Y, et al. Primary skeletal muscle involvement in chorea-acanthocytosis. Mov Disord. 2007 Apr 30. 22(6):848-52. [Medline].

  96. Sano A. [Hereditary chorea--update]. Rinsho Shinkeigaku. 2004 Nov. 44(11):932-4. [Medline].

  97. Scheid R, Bader B, Ott DV, Merkenschlager A, Danek A. Development of mesial temporal lobe epilepsy in chorea-acanthocytosis. Neurology. 2009 Oct 27. 73(17):1419-22. [Medline].

  98. Schneider SA, Aggarwal A, Bhatt M, Dupont E, Tisch S, Limousin P. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology. 2006 Sep 26. 67(6):940-3. [Medline].

  99. Senda Y, Koike Y, Sugimura K, et al. [Chorea-acanthocytosis with catecholamine abnormality and orthostatic hypotension--a case report]. Rinsho Shinkeigaku. 1987 Jul. 27(7):898-903. [Medline].

  100. Serra S, Arena A, Xerra A, et al. Amyotrophic choreoacanthocytosis: is it really a very rare disease?. Ital J Neurol Sci. 1986 Oct. 7(5):521-4. [Medline].

  101. Serra S, Xerra A, Arena A. Amyotrophic choreo-acanthocytosis: a new observation in southern Europe. Acta Neurol Scand. 1986 May. 73(5):481-6. [Medline].

  102. Shah JR, Patkar DP, Kamat RN. A case of McLeod phenotype of neuroacanthocytosis brain MR features and literature review. Neuroradiol J. 2013 Feb. 26(1):21-6. [Medline].

  103. Sobue G, Mukai E, Fujii K, et al. Peripheral nerve involvement in familial chorea-acanthocytosis. J Neurol Sci. 1986 Dec. 76(2-3):347-56. [Medline].

  104. Sotaniemi KA. Chorea-acanthocytosis. Neurological disease with acanthocytosis. Acta Neurol Scand. 1983 Jul. 68(1):53-6. [Medline].

  105. Spencer SE, Walker FO, Moore SA. Chorea-amyotrophy with chronic hemolytic anemia: a variant of chorea-amyotrophy with acanthocytosis. Neurology. 1987 Apr. 37(4):645-9. [Medline].

  106. Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985 Mar. 35(3):366-70. [Medline].

  107. Sugihara R, Ueyama H, Fujimoto S, et al. [A case of McLeod syndrome]. Rinsho Shinkeigaku. 1998 Oct-Nov. 38(10-11):915-9. [Medline].

  108. Swash M, Schwartz MS, Carter ND, et al. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain. 1983 Sep. 106 (Pt 3):717-33. [Medline].

  109. Takahashi Y, Kojima T, Atsumi Y, et al. [Case of chorea-acanthocytosis with various psychotic symptoms]. Seishin Shinkeigaku Zasshi. 1983. 85(8):457-72. [Medline].

  110. Takashima H, Sakai T, Iwashita H, et al. A family of McLeod syndrome, masquerading as chorea-acanthocytosis. J Neurol Sci. 1994 Jun. 124(1):56-60. [Medline].

  111. Terao S, Sobue G, Takahashi M, et al. [Disturbance of hypothalamic-pituitary hormone secretion in familial chorea-acanthocytosis]. No To Shinkei. 1995 Jan. 47(1):57-61. [Medline].

  112. Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci. 2006 Jan. 37(1):46-9. [Medline].

  113. Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci. 2006 Jan. 37(1):46-9. [Medline].

  114. Tsai CH, Chen RS, Chang HC, et al. Acanthocytosis and spinocerebellar degeneration: a new association?. Mov Disord. 1997 May. 12(3):456-9. [Medline].

  115. Tschopp L, Raina G, Salazar Z, Micheli F. Neuroacanthocytosis and carbamazepine responsive paroxysmal dyskinesias. Parkinsonism Relat Disord. 2008. 14(5):440-2. [Medline].

  116. Villegas A, Moscat J, Vazquez A, et al. A new family with hereditary choreo-acanthocytosis. Acta Haematol. 1987. 77(4):215-9. [Medline].

  117. Walker RH, Danek A, Dobson-Stone C, et al. Developments in neuroacanthocytosis: expanding the spectrum of choreatic syndromes. Mov Disord. 2006 Nov. 21(11):1794-805. [Medline].

  118. Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol. 2007 Nov. 7(6):360-73. [Medline].

  119. Witt TN, Danek A, Reiter M, et al. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. J Neurol. 1992 Jul. 239(6):302-6. [Medline].

  120. Woodruff RK, Wiley JS, Bell WR, et al. Acanthocytosis and haemolytic anaemia due to the McLeod blood group. Aust N Z J Med. 1981 Apr. 11(2):184-7. [Medline].

  121. Zyskowski LP, Bunch TW, Hoagland HC, et al. Mcleod syndrome (hemolysis, acanthocytosis, and increased serum creatine kinase): potential confusion with polymyositis. Arthritis Rheum. 1983 Jun. 26(6):806-8. [Medline].

 
Previous
Next
 
Patient with choreoacanthocytosis. A: Note self-mutilation of the lips owing to orofacial dyskinesia. B: Peripheral blood smear exhibits acanthocytes (Wright-Giemsa, original magnification, >100). C: Coronal view of T1-weighted MRI shows atrophy of the caudate nuclei. Archives of Neurology 64(11):1661-1664 2007 Copyright © 2010 American Medical Association.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.